- Home
- CHRS vs CURR Comparison
CHRS vs CURR Comparison
Compare CHRS & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CURR
- Stock Information
- Founded
- CHRS 2010
- CURR 2013
- Country
- CHRS United States
- CURR Singapore
- Employees
- CHRS N/A
- CURR N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CURR Business Services
- Sector
- CHRS Health Care
- CURR Consumer Discretionary
- Exchange
- CHRS Nasdaq
- CURR Nasdaq
- Market Cap
- CHRS 134.4M
- CURR 133.1M
- IPO Year
- CHRS 2014
- CURR N/A
- Fundamental
- Price
- CHRS $1.07
- CURR $1.83
- Analyst Decision
- CHRS Strong Buy
- CURR
- Analyst Count
- CHRS 4
- CURR 0
- Target Price
- CHRS $5.38
- CURR N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- CURR 569.7K
- Earning Date
- CHRS 03-12-2025
- CURR 03-04-2025
- Dividend Yield
- CHRS N/A
- CURR N/A
- EPS Growth
- CHRS N/A
- CURR N/A
- EPS
- CHRS N/A
- CURR N/A
- Revenue
- CHRS $304,340,000.00
- CURR $48,723,898.00
- Revenue This Year
- CHRS $2.07
- CURR N/A
- Revenue Next Year
- CHRS N/A
- CURR N/A
- P/E Ratio
- CHRS N/A
- CURR N/A
- Revenue Growth
- CHRS 44.19
- CURR N/A
- 52 Week Low
- CHRS $0.66
- CURR $1.19
- 52 Week High
- CHRS $2.65
- CURR $7.08
- Technical
- Relative Strength Index (RSI)
- CHRS 39.03
- CURR N/A
- Support Level
- CHRS $1.06
- CURR N/A
- Resistance Level
- CHRS $1.16
- CURR N/A
- Average True Range (ATR)
- CHRS 0.08
- CURR 0.00
- MACD
- CHRS 0.00
- CURR 0.00
- Stochastic Oscillator
- CHRS 5.56
- CURR 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.